GlassScriptPhysician profile
Neil D Chevallier
NPI 1063835577
$6,993.76
in general payments reported to CMS, 2019-2025
26 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,433 · 2022: $986 · 2023: $1,475 · 2024: $1,403 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.75 |
| Education | $352.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.78 | 2021-2025 | |
| Janssen Biotech, INC. | $906.92 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $631.86 | 2021-2025 | Bimzelx |
| Incyte Corporation | $589.92 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $470.36 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $401.44 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $395.57 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $357.75 | 2021-2025 | |
| Genzyme Corporation | $351.59 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.25 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $241.68 | 2021-2025 | Adbry |
| Amgen INC. | $221.93 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $208.26 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $178.73 | 2021-2023 | Ilumya |
| Almirall LLC | $117.51 | 2023-2025 | Seysara, Klisyri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $103.41 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Biofrontera INC. | $56.04 | 2024-2025 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.73 | 2023-2024 | Spevigo, Cyltezo |
| Organon LLC | $48.51 | 2025 | Vtama |
| Krystal Biotech INC | $23.49 | 2023 | Vyjuvek |
| Mylan Institutional INC. | $23.36 | 2023 | Hulio |
| Vyne Pharmaceuticals INC. | $20.70 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $16.87 | 2025 | Valchlor |
| Sandoz INC. | $15.10 | 2024 | Hyrimoz |
| Dermavant Sciences, INC. | $15.01 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Chevallier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.